Pfizer PFE

NYSE · Pharmaceutical Preparations · $175.5B

$29.88−2.96%Nov 5 close · Databento

Every report since 2023 →

🔒 Click to interact · scroll moves the page

PFE Wire Story Reactions & EOD Technical StudyDaily closes (Databento EOD) pinned with every AlgoThesis Wire story (dot colour = next trading day close) and SEC filing

Nov 5, 2026CLOSE $29.881D −2.96%3M +10.46%SMA20 $29.70SMA50 $28.72RSI(14) 54.1

29.88

RSI (14, Wilder EOD) · 70 Overbought / 30 OversoldRSI 54.1

Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.

1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.

The numbers

fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento

Market cap$175.5B

EV / True FCF28.9x

Revenue$62.6B −1.6%

True FCF (ex-SBC)$8.3B −7.7%

Rule of 4012.9%

True FCF Yield4.7%

EPS, diluted$1.36 −3.5%

Modern Valuation (EOD)

Market Cap$175.5B

Enterprise Value$239.1B

EV / True FCF28.89

EV / FCF26.35

EV / Gross Profit—

EV / EBIT—

EV / Sales3.82

P / E (GAAP)22.58

P / FCF19.34

P / Oper. CF14.99

P / Book2.02

Owner & Cash Yields

True FCF Yield4.7%

FCF Yield5.2%

Owner Earn. Yield6.2%

Earnings Yield4.4%

Shareholder Yield−0.5%

Buyback Yield0.0%

Dividend Yield5.76%

Dividend / sh$1.72

Payout Ratio—

FCF / sh$1.59

EPS (diluted)$1.36

Compounder & Returns

Rule of 4012.9%

ROIC—

Cash ROIC (CROIC)6.0%

GP / Assets—

ROE9.0%

ROA3.7%

Gross Margin—

Oper. Margin—

Net Margin12.4%

FCF Margin14.5%

True FCF Margin13.2%

Quality & Dilution

Cash Conversion117%

Accrual Ratio−1.9%

SBC % of FCF8.8%

SBC % of Rev1.3%

Reinvest. Rate23%

Sales Growth Y/Y−1.6%

Sales 3Y CAGR−14.8%

EPS Growth Y/Y−3.5%

FCF Growth Y/Y−7.7%

FCF 3Y CAGR−29.6%

Share Change Y/Y+0.2%

Balance Sheet & Scale

Revenue (FY)$62.6B

Gross Profit (FY)—

Oper. Income (FY)—

GAAP Net Income$7.8B

True FCF (ex-SBC)$8.3B

Cash & Equiv$1.2B

Total Debt$64.8B

Net Cash (Debt)$-63.6B

Net Cash % MCap−36.2%

Debt / FCF (yrs)7.1y

Current Ratio1.165.70B sh

Price & Technicals (EOD)

Perf Week−0.23%

Perf Month+6.71%

Perf Quarter+11.66%

Perf Half Y+12.84%

Perf YTD+8.58%

SMA 20 Dist+0.61%$29.70

SMA 50 Dist+4.06%$28.72

SMA 100 Dist+10.25%$27.10

Window High−2.96%$30.79

Window Low+26.24%$23.67

RSI (14) · Vol54.126%v

Income Distribution & Cash Flow ConversionHow every dollar of PFE revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow

Where Every $100 of Revenue Goes (FY2025)

Cost of Revenue (COGS)$16.1B ($25.7 / $100)

SG&A & Other OpEx$13.8B ($22.0 / $100)

Tax & Non-Operating$38.7B ($61.9 / $100)

Net Profit Kept$7.8B ($0.0 / $100)

Earnings Quality: GAAP Profit → True Owner Cash (FY2025)

GAAP Net Income$7.8B (12.4% margin)

Operating Cash Flow (OCF)$11.7B(18.7% of rev)

Less: Capital Expenditures−$2.6B(4.2% of rev)

Standard Free Cash Flow (FCF)$9.1B(14.5% margin)

Less: Stock-Based Comp (SBC)−$799.0M(8.8% of FCF)

True FCF (Owner Cash ex-SBC)$8.3B(13.2% of rev)

Revenue by fiscal year

Operating leverage — margins

GrossOperatingNet

Line Item (USD)	FY2021	FY2022	FY2023	FY2024	FY2025	YoY Δ	4Y CAGR
Income Statement
Revenue	$81.3B	$101.2B	$59.6B	$63.6B	$62.6B	−1.6%	−6.3%
Cost of Revenue (COGS)	$30.8B	$34.3B	$25.0B	$17.9B	$16.1B	−10.0%	−15.0%
Selling, General & Admin (SG&A)	$12.7B	$13.7B	$14.8B	$14.7B	$13.8B	−6.4%	+2.1%
Interest Expense	$1.3B	$1.2B	$2.2B	$3.1B	$2.7B	−13.6%	+19.9%
Income Tax Expense	$1.9B	$3.3B	$-1.1B	$-28.0M	$-266.0M	−850.0%	—
GAAP Net Income	$22.0B	$31.4B	$2.1B	$8.0B	$7.8B	−3.2%	−22.9%
Diluted EPS	$3.85	$5.47	$0.37	$1.41	$1.36	−3.5%	−22.9%
Diluted Shares	5.71B	5.73B	5.71B	5.70B	5.71B	+0.2%	+0.0%
Balance Sheet
Cash & Equivalents	$2.0B	$468.0M	$2.9B	$1.1B	$1.2B	+8.1%	−11.9%
Inventory	$9.1B	$9.0B	$10.2B	$10.9B	$10.7B	−1.8%	+4.1%
Total Current Assets	$59.7B	$51.3B	$43.3B	$50.4B	$42.9B	−14.8%	−7.9%
Total Assets	$181.5B	$197.2B	$226.5B	$213.4B	$208.2B	−2.5%	+3.5%
Total Current Liabilities	$42.7B	$42.1B	$47.8B	$43.0B	$37.0B	−14.0%	−3.5%
Total Debt (Short + Long Term)	$38.4B	$35.8B	$71.9B	$64.4B	$64.8B	+0.7%	+13.9%
Total Liabilities	$104.0B	$101.3B	$137.2B	$124.9B	$121.4B	−2.8%	+3.9%
Stockholders' Equity	$77.5B	$95.9B	$89.3B	$88.5B	$86.8B	−1.9%	+2.9%
Net Cash / (Net Debt)	$-36.5B	$-35.4B	$-69.0B	$-63.2B	$-63.6B	−0.6%	—
Invested Capital	$113.9B	$131.3B	$158.3B	$151.7B	$150.4B	−0.9%	+7.2%
Cash Flow & Capital Allocation
Operating Cash Flow (OCF)	$32.6B	$29.3B	$8.7B	$12.7B	$11.7B	−8.2%	−22.6%
Depreciation & Amortization (D&A)	$5.2B	$5.1B	$6.3B	$7.0B	$6.6B	−6.0%	+6.2%
Stock-Based Compensation (SBC)	$1.2B	$872.0M	$525.0M	$877.0M	$799.0M	−8.9%	−9.3%
Capital Expenditures (CapEx)	$2.7B	$3.2B	$3.9B	$2.9B	$2.6B	−9.6%	−0.8%
Free Cash Flow (FCF)	$29.9B	$26.0B	$4.8B	$9.8B	$9.1B	−7.7%	−25.8%
True FCF (ex-SBC Owner Cash)	$28.7B	$25.2B	$4.3B	$9.0B	$8.3B	−7.6%	−26.7%
Share Repurchases (Buybacks)	$0	$2.0B	$0	$0	$0	—	—

Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.

On the Wire

what PFE did at the next close after each story

Aug 18

Pfizer PFE agrees to settle Depo-Provera litigation for over $1.2 billion

PR Newswire · 6:15 AM ET

+1.41%

What happened · big days

9 big days in a year, and what we hold on each

A big day is a close more than 2.76% from the one before, three times PFE’s median day (0.92%). On 4 of the 9, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.

every other trading daya big day, numbered in the list below±2.76%Hover a bar for its day. Click a big day to open it.

Shaded: since our stories began, Jun 10. Tap a bar for its day.

#DayPFEWhat we hold that dayGroup (median of 4) · each

1 Nov 11, 2025+4.59%
Before our storiesgroup +2.9%, moved with PFE
1Nov 11, 2025+4.59%
Before our stories
+2.9% moved with PFEMRK +4.8 · ABBV +3.0 · JNJ +2.9 · LLY +2.3
2 Nov 14, 2025−2.83%
Before our storiesgroup +0.1%, did not move with it
2Nov 14, 2025−2.83%
Before our stories
+0.1% did not move with itMRK −0.0 · ABBV +0.0 · LLY +0.2 · JNJ +0.3
3 Dec 16, 2025−3.41%
Before our storiesgroup −1.8%, moved with PFE
3Dec 16, 2025−3.41%
Before our stories
−1.8% moved with PFEJNJ −2.3 · MRK −2.0 · ABBV −1.7 · LLY −0.7
4 Feb 3, 2026−3.34%
Resultsgroup +0.5%, did not move with it
4Feb 3, 2026−3.34%
ResultsFirst close after the Feb 3 results filing
+0.5% did not move with itLLY −3.9 · ABBV +0.0 · JNJ +1.0 · MRK +2.2
5 Feb 4, 2026+3.92%
Before our storiesgroup +1.4%, did not move with it
5Feb 4, 2026+3.92%
Before our stories
+1.4% did not move with itLLY +10.3 · MRK +2.1 · JNJ +0.6 · ABBV −3.8
6 Mar 17, 2026+3.16%
Before our storiesgroup −1.4%, did not move with it
6Mar 17, 2026+3.16%
Before our stories
−1.4% did not move with itMRK +0.4 · ABBV −0.8 · JNJ −2.1 · LLY −5.9
7 May 8, 2026−3.02%
Before our storiesgroup −0.7%, did not move with it
7May 8, 2026−3.02%
Before our stories
−0.7% did not move with itLLY −2.7 · MRK −0.8 · ABBV −0.6 · JNJ −0.5
8 Aug 19, 2026+3.63%
Nothing on PFEgroup +3.6%, moved with PFE
8Aug 19, 2026+3.63%
Nothing on PFENo PFE story, brief or results filing in our record that day
+3.6% moved with PFEMRK +12.6 · LLY +4.5 · ABBV +2.7 · JNJ +0.8
9 Oct 14, 2026+2.96%
Nothing on PFEgroup +3.5%, moved with PFE
9Oct 14, 2026+2.96%
Nothing on PFENo PFE story, brief or results filing in our record that day
+3.5% moved with PFEMRK +3.8 · LLY +3.6 · ABBV +3.3 · JNJ +2.1

A story on the same day is not a cause, and a group move is not proof either. Group: the median of LLY, JNJ, ABBV and MRK that day, the largest companies in PFE’s SEC industry; “moved with PFE” means the same direction and at least half the size.

What’s next · results

Before the next report: what the first day after the last four did

Six trading days after each results filing (SEC 8-K, Item 2.02). PFE reports before the open, so day 1 is that day’s close. 1 of 4 times, day 6 ended on the same side as day 1.

Reported Nov 4, 2025

day 1−1.46%day 6+3.45%

Reported Feb 3, 2026

day 1−3.34%day 6+3.56%

Reported May 5, 2026

day 1+0.57%day 6−1.63%

Reported Aug 4, 2026

day 1+1.52%day 6+6.35%

Next report: expected early FebruaryEstimated from the dates of its last four results filings. Not announced. Since the Nov 3 report: +0.39%. Four reports is a small sample.

Every report since 2023 →

Each line is PFE’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.

Same industry

PFE against four drug peers, a year at 100

PFE is up 26.0% in a year. Merck is up 74.3%, Eli Lilly 53.4%, Johnson & Johnson 48.1% and AbbVie 34.5%. All four did more. Weekly closes, Nov 7, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

PFE +26.0%. Merck +74.3%, Eli Lilly +53.4%, Johnson & Johnson +48.1%, AbbVie +34.5%. Weekly closes, Nov 7, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in PFE’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

LLY	Eli Lilly	$1.33T	−3.76%
JNJ	Johnson & Johnson	$665.9B	−1.45%
ABBV	AbbVie	$521.0B	−2.24%
MRK	Merck	$371.0B	−2.27%
ABT	Abbott	$199.9B	−1.65%
VRTX	Vertex Pharmaceuticals	$139.2B	−1.19%
BMY	Bristol Myers Squibb	$131.1B	−1.65%
REGN	Regeneron Pharmaceuticals	$101.1B	−2.98%